Update 03.16 PM EST: Adds comments from ResMed The U.S. Food and Drug Administration (FDA) on Thursday classified a product ...

The renowned medical device company has a market capitalization of $35.10 billion. RMD has an earnings yield of 14.8%, outpacing the industry’s 14.4%. The company’s earnings surpassed estimates in ...

An anxiety drug is being voluntarily recalled over an error that could be “life-threatening”. Endo, Inc. issued a voluntary recall for Clonazepam tablets “due ...

ResMed stands to benefit from Philips’ significant product recall and the launch of its new flagship product, AirSense 11. Market share gains from Philips’ product recall may be limited as ...

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea ...

While ResMed has maintained its dominance in the sleep apnoea market, analysts said the return of Dutch rival Philips to the US market after a product recall was a potential disruptor.

ResMed Inc (NYSE:RMD) reports a robust 11% increase in net revenue year-over-year. Significant growth in Sleep and Breathing Health segment, showcasing an 11% rise in sales. Strong gross margin ...